NEDD9 Promotes Oncogenic Signaling in Mammary Tumor Development.

Eugene Izumchenko, Mahendra K Singh, Olga V Plotnikova, Nadezhda Tikhmyanova, Joy L Little, Ilya G Serebriiskii, Sachiko Seo, Mineo Kurokawa, Brian L Egleston, Andres Klein-Szanto, Elena N Pugacheva, Richard R Hardy, Marina Wolfson, Denise C Connolly, Erica A Golemis

Programs in Molecular and Translational Medicine and Immunology and Women's Cancer, Fox Chase Cancer Center; Department of Biochemistry, Drexel University School of Medicine, Philadelphia, Pennsylvania; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; Department of Molecular Biology and Medical Biotechnology, Russian State Medical University, Moscow, Russia; Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; and Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia.

Journal Article: Cancer Research (impact factor: 7.54). 10/2009; DOI: 10.1158/0008-5472.CAN-09-0795

Abstract

In the past 3 years, altered expression of the HEF1/CAS-L/NEDD9 scaffolding protein has emerged as contributing to cancer metastasis in multiple cancer types. However, whereas some studies have identified elevated NEDD9 expression as prometastatic, other work has suggested a negative role in tumor progression. We here show that the Nedd9-null genetic background significantly limits mammary tumor initiation in the MMTV-polyoma virus middle T genetic model. Action of NEDD9 is tumor cell intrinsic, with immune cell infiltration, stroma, and angiogenesis unaffected. The majority of the late-appearing mammary tumors of MMTV-polyoma virus middle T;Nedd9(-/-) mice are characterized by depressed activation of proteins including AKT, Src, FAK, and extracellular signal-regulated kinase, emphasizing an important role of NEDD9 as a scaffolding protein for these prooncogenic proteins. Analysis of cells derived from primary Nedd9(+/+) and Nedd9(-/-) tumors showed persistently reduced FAK activation, attachment, and migration, consistent with a role for NEDD9 activation of FAK in promoting tumor aggressiveness. This study provides the first in vivo evidence of a role for NEDD9 in breast cancer progression and suggests that NEDD9 expression may provide a biomarker for tumor aggressiveness. [Cancer Res 2009;69(18):7198-206].

Source: PubMed

Comments on this publication

ResearchGate members can add comments. Sign up now and post your comment!

Similar publications

Science & Research Jobs

Keywords

angiogenesis unaffected
 
breast cancer progression
 
cancer metastasis
 
depressed activation
 
FAK activation
 
HEF1/CAS-L/NEDD9 scaffolding protein
 
immune cell infiltration
 
late-appearing mammary tumors
 
MMTV-polyoma virus middle T genetic model
 
multiple cancer types
 
NEDD9
 
NEDD9 activation
 
NEDD9 expression
 
Nedd9-null genetic background
 
negative role
 
prooncogenic proteins
 
scaffolding protein
 
tumor aggressiveness
 
tumor progression
 
vivo evidence